Good morning, everyone, and welcome to another working week. We hope the weekend respite was relaxing and invigorating because that oh-too-familiar routine of meetings, deadlines, and the like has returned with a vengeance. You knew this would happen, yes? To cope, we are relying, as always, on a cuppa stimulation. Our choice today is oolong. Please feel free to join us. Meanwhile, here is the latest menu of tidbits for you to peruse. We hope that your day is absolutely smashing and that you conquer the world. And of course, do keep in touch. We treasure your feedback and insights. …
AstraZeneca stock fell as investors balked at reports of merger talks with Bristol Myers Squibb about forming what would become one of the world’s biggest drugmakers, with a combined value of nearly $400 billion, Reuters explains. Shares in AstraZeneca were down 5.5% so far on Monday as investors and analysts noted the U.K.’s biggest drugmaker had little obvious need for a transformative acquisition despite potential financial benefits. Meanwhile, Bristol Myers shares were up about 5% in U.S. premarket trading. Jefferies analyst Michael Leuchten wrote in an investor note that a deal “would be more than a head scratcher.” The potential merger raises questions about the strategic rationale behind the move, particularly given AstraZeneca’s strong portfolio of existing products and pipeline. Additionally, the integration of two large pharmaceutical companies can be complex and time-consuming, requiring significant resources and effort to combine operations, streamline processes, and eliminate redundancies.
Amgen disclosed that hackers stole company data and patient health information in a cybersecurity incident involving cloud storage systems run by third-party providers, becoming the latest health care firm to disclose a breach, Reuters writes. On July 29, Amgen determined the incident was material, based on its evaluation of how many files appeared to be affected and the possibility that the information in those files could be sensitive, according to a regulatory filing. To date, Amgen has not found any impact on its products, manufacturing operations, financial reporting systems, or its ability to meet patient needs. The breach highlights the importance of robust cybersecurity measures in the healthcare industry, particularly when it comes to protecting sensitive patient information. Cloud storage systems, in particular, can be vulnerable to cyber threats if not properly secured, and companies must ensure that their third-party providers have adequate security protocols in place to prevent such incidents.
The incident also shows the need for transparency and prompt disclosure in the event of a cybersecurity breach. Amgen’s decision to notify the public and regulatory authorities in a timely manner demonstrates a commitment to accountability and patient trust. Furthermore, the company’s evaluation of the incident and its potential impact on patients and operations suggests a thorough and meticulous approach to managing the breach. As the healthcare industry continues to rely on digital technologies and cloud-based systems, the risk of cyber threats will only continue to grow, making it essential for companies to prioritize cybersecurity and have robust incident response plans in place.
Already have an account? Log in
Related: New York advances assisted dying legislation
This article is exclusive to STAT+ subscribers
Unlock this article — plus in-depth analysis, newsletters, premium events, and news alerts.
Already have an account? Log in
To read the rest of this story subscribe to STAT+.